title: Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.
abstract: Despite the use of highly active antiretroviral therapies (HAART), a majority of Human Immunodeficiency Virus Type 1 (HIV) infected individuals continually develop HIV - Associated Neurocognitive Disorders (HAND), indicating that host inflammatory mediators, in addition to viral proteins, may be contributing to these disorders. Consistent with this notion, we have previously shown that levels of the inflammatory mediator soluble CD40 ligand (sCD40L) are elevated in the plasma and cerebrospinal fluid (CSF) of HIV infected, cognitively impaired individuals, and that excess sCD40L can contribute to blood brain barrier (BBB) permeability in vivo, thereby signifying the importance of this inflammatory mediator in the pathogenesis of HAND. Here we demonstrate that the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) induces the release of circulating sCD40L in both HIV infected individuals and in an in vitro suspension of washed human platelets, which are the main source of circulating sCD40L. Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3β) in platelets, and we now show that valproic acid (VPA), a known GSK3β inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. Collectively these results have important implications in determining the pro-inflammatory role that some antiretroviral regimens may have. The use of antiretrovirals remains the best strategy to prevent HIV-associated illnesses, including HAND, however these drugs have clear limitations to this end, and thus, these results underscore the need to develop adjunctive therapies for HAND that can also minimize the undesired negative effects of the antiretrovirals.
authors.affiliation: Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America.
authors.forename: Donna C
authors.initials: DC
authors.lastname: Davidson
authors.forename: Giovanni
authors.initials: G
authors.lastname: Schifitto
authors.forename: Sanjay B
authors.initials: SB
authors.lastname: Maggirwar
mesh_terms: D000480:Alkynes; D048588:Benzoxazines / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000378:metabolism; D023201:CD40 Ligand / Q000097:blood* / Q000134:cerebrospinal fluid*; D003521:Cyclopropanes; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005786:Gene Expression Regulation; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D048670:MAP Kinase Kinase 4 / Q000378:metabolism; D008297:Male; D010539:Permeability; D010766:Phosphorylation; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D014635:Valproic Acid / Q000494:pharmacology*
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D004791:Enzyme Inhibitors; D018894:Reverse Transcriptase Inhibitors; D023201:CD40 Ligand; D014635:Valproic Acid; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D048670:MAP Kinase Kinase 4; C098320:efavirenz
references.citation: Am J Pathol. 2012 Oct;181(4):1414-25
references.pmid: 22863953
references.citation: Circulation. 2001 Jan 30;103(4):491-5
references.pmid: 11157711
references.citation: Int Rev Psychiatry. 2008 Feb;20(1):3-13
references.pmid: 18240058
references.citation: Lancet. 2005 Aug 13-19;366(9485):549-55
references.pmid: 16099290
references.citation: Neurology. 2010 Dec 7;75(23):2087-96
references.pmid: 21135382
references.citation: Ann Neurol. 2010 Jun;67(6):699-714
references.pmid: 20517932
references.citation: J Neurovirol. 2006 Oct;12(5):403-6
references.pmid: 17065134
references.citation: Blood. 1999 Dec 1;94(11):3800-5
references.pmid: 10572094
references.citation: Neurology. 2006 Mar 28;66(6):919-21
references.pmid: 16510768
references.citation: Eur J Neurosci. 2001 May;13(10):1913-22
references.pmid: 11403684
references.citation: Viral Immunol. 2006 Summer;19(3):363-72
references.pmid: 16987056
references.citation: Blood. 2010 May 20;115(20):4083-92
references.pmid: 20231429
references.citation: Mol Diagn Ther. 2008;12(1):25-43
references.pmid: 18288880
references.citation: Neuropathol Appl Neurobiol. 1999 Apr;25(2):123-33
references.pmid: 10216000
references.citation: Blood. 2003 Apr 1;101(7):2661-6
references.pmid: 12480714
references.citation: Neurol Clin. 2008 Aug;26(3):799-819, x
references.pmid: 18657727
references.citation: Clin Infect Dis. 1998 May;26(5):1072-3
references.pmid: 9597227
references.citation: J Thromb Haemost. 2008 Dec;6(12):2007-16
references.pmid: 18826389
references.citation: Curr Opin Neurol. 2009 Jun;22(3):315-20
references.pmid: 19300249
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4328-31
references.pmid: 15504860
references.citation: J Immunol. 2011 Jan 1;186(1):584-91
references.pmid: 21115729
references.citation: Platelets. 2001 Mar;12(2):74-82
references.pmid: 11297035
references.citation: PLoS One. 2012;7(12):e51793
references.pmid: 23251626
references.citation: J Neurosci. 2003 Oct 8;23(27):9162-70
references.pmid: 14534250
references.citation: PLoS One. 2010 Feb 23;5(2):e9390
references.pmid: 20186346
references.citation: AIDS. 2011 Nov 28;25(18):2243-8
references.pmid: 21941165
references.citation: Circulation. 2002 Aug 20;106(8):896-9
references.pmid: 12186789
references.citation: Blood. 2008 Apr 1;111(7):3522-30
references.pmid: 18218855
references.citation: J Neurovirol. 2011 Oct;17(5):487-95
references.pmid: 21956288
references.citation: Clin Diagn Lab Immunol. 2002 May;9(3):558-61
references.pmid: 11986259
references.citation: Nature. 2001 Apr 19;410(6831):988-94
references.pmid: 11309629
references.citation: Ann Neurol. 1995 Nov;38(5):755-62
references.pmid: 7486867
references.citation: J Immunol. 2007 Mar 1;178(5):3226-36
references.pmid: 17312171
references.citation: Blood. 2006 Feb 1;107(3):947-54
references.pmid: 16223779
references.citation: J Acquir Immune Defic Syndr. 2010 Jun;54(2):217-8
references.pmid: 20505474
references.citation: J Neurosci. 2010 Jul 14;30(28):9454-64
references.pmid: 20631174
references.citation: Am J Pathol. 2002 Feb;160(2):559-67
references.pmid: 11839576
references.citation: J Infect Dis. 2002 Feb 15;185(4):456-62
references.pmid: 11865397
references.citation: Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2424-33
references.pmid: 21071692
references.citation: Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):247-58
references.pmid: 22507337
references.citation: J Infect Dis. 2011 Oct 15;204(8):1202-10
references.pmid: 21917893
references.citation: Arch Neurol. 2007 Sep;64(9):1264-72
references.pmid: 17846264
references.citation: Blood. 2008 Nov 15;112(10):4051-60
references.pmid: 18755987
references.citation: Int Rev Psychiatry. 2008 Feb;20(1):25-31
references.pmid: 18240060
references.citation: PLoS One. 2010 Jun 30;5(6):e11383
references.pmid: 20614021
references.citation: AIDS. 2001 Jan 5;15(1):71-5
references.pmid: 11192870
references.citation: FEBS Lett. 2003 Oct 9;553(1-2):173-8
references.pmid: 14550568